Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study
Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
Ricca et al., 2000)
Using the correct statistical test for the equality of regression coefficients
US$ 24.33
US$ 29.86
US$ 21.84
US$ 28.35
US$ 29.09
US$ 25.30
